primary biliary cholangitis pbc
play

Primary Biliary Cholangitis (PBC) Formerly known as primary biliary cirrhosis Chronic, autoimmune disease of the liver that slowly destroys the medium-sized bile ducts (intrahepatic bile ducts) Eventually causes cholestasis

0 downloads 3 Views 570 KB Size Report
  1. Primary Biliary Cholangitis (PBC) • Formerly known as primary biliary cirrhosis • Chronic, autoimmune disease of the liver that slowly destroys the medium-sized bile ducts (intrahepatic bile ducts) • Eventually causes cholestasis (disruption/obstruction of bile flow), cirrhosis (scarring and deterioration of liver), and liver failure 2

  2. Primary Biliary Cholangitis: Etiology and Epidemiology • Current research suggests PBC is an autoimmune disease; the cause is still unknown. • Although relatively rare, PBC is the most common liver disease associated with chronic cholestasis in adults. • Highest prevalence is adult women: approximately 95% of cases occur in women aged 35 to 70, and 90% of all cases are women. 3

  3. Primary Biliary Cholangitis: Etiology and Epidemiology (cont.) • PBC is not a hereditary disease, but patterns of occurrence appear. • There is a higher familial rate of incidence, especially between mothers and daughters, as well as in identical twins. • For those more genetically likely to develop PBC, environmental factors can trigger or worsen the disease — such as smoking or exposure to certain medications or toxic chemicals. 4

  4. Liver Physiology • The body’s largest internal organ • Essential Functions for the Body – Absorbing, storing, and processing nutrients from food – Making new proteins, such as albumin and clotting factors – Producing bile – Removing waste products the kidneys cannot remove (fats, cholesterol, toxins, and medications) 5

  5. Liver Physiology and Presentation of Primary Biliary Cholangitis • In patients with PBC, the bile ducts are slowly destroyed by inflammation, which causes bile to remain in the liver, leading to scarring, cirrhosis, and liver failure. • As many as half of patients with PBC present without symptoms. 6

  6. Primary Biliary Cholangitis: Presentation and Associated Disorders • Most Common Symptoms – Fatigue – Pruritus • Other Symptoms – Dry eyes and mouth – Fluid build-up in the ankles and abdomen – Collection of fatty deposits in the skin around the eye – Jaundice • Associated Disorders – Problems with tear and salivary glands – Sjögren's syndrome, celiac disease, rheumatoid arthritis, and especially thyroid – Cholesterol gallstones 7

  7. Primary Biliary Cholangitis: Diagnosis • 95% of cases occur in women aged 35 to 70. • Often discovered through abnormal results on routine liver blood tests. • Doctors need to do several tests to confirm a diagnosis of PBC. • Most characteristic laboratory finding in PBC is the presence of positive antimitochondrial antibody (AMA), generally in a titer of 1:80 or higher. – More than 95% of patients with PBC have a positive AMA. • Liver biopsy is often performed to confirm diagnosis. 8

  8. Primary Biliary Cholangitis: Pathophysiology and Progression • As PBC progresses, it Stage 1: Inflammation, abnormal connective tissue, or both, may become confined to the portal areas morphologically indistinguishable from Stage 2: Inflammation, fibrosis, or other forms of cirrhosis. both, confined to the portal and periportal areas • Liver biopsy helps evaluate the stage of Stage 3: Bridging fibrosis PBC, which has 4 Stage 4: Cirrhosis histologic stages. 9

  9. Primary Biliary Cholangitis: Treatment • Early detection allows physicians to treat the disease before the liver is severely damaged. • Patients most often take a daily dose of a drug called ursodiol (ursodeoxycholic acid or UDCA), a naturally occurring bile acid. • In patients who do not respond or cannot tolerate UDCA, there are alternative therapies including the addition of obeticholic acid ( Ocaliva ), recently approved by the FDA for treatment of PBC in combination with UDCA. Ocaliva increases bile flow from the liver and suppresses bile acid production in the liver, thus reducing the exposure of the liver to toxic levels of bile acids. 10

  10. Primary Biliary Cholangitis: Treatment • Ursodiol and Ocaliva improve the liver’s ability to function in PBC patients. • Extends life expectancy and may delay the need for a liver transplant. • Patients rarely experience side effects from ursodiol. • Obeticholic acid (Ocaliva) may aggravate or cause itching in some cases and can cause elevations in plasma lipids. Both of these side effects may respond to other medications. • Fenofibrate may also be considered as an alternative therapy, although it is not yet FDA approved for PBC. 11

  11. Primary Biliary Cholangitis: Complications and Treatment • Health care providers can treat symptoms and side effects of PBC – Itching: antihistamines; bile acid binding resins (cholestyramine); rifampicin. – Dry eyes and mouth: artificial tears and saliva substitutes – Portal hypertension: beta-blocker or nitrate – Varices: beta-blockers – Edema and ascites: diuretics – Osteoporosis: bisphosphonate medications – Gallstones and bile duct stones: surgery • A health care provider may consider a liver transplant when cirrhosis leads to liver failure or treatment for complications is ineffective. 12

  12. Primary Biliary Cholangitis: Lifestyle Changes and Health • A reduced sodium diet • A healthy lifestyle will • Drinking ample water help patients with PBC • Taking calcium and Vitamin D feel better — and may supplements relieve or prevent some • Avoiding or reducing the of the secondary consumption of alcohol • symptoms of PBC. Reducing stress • Exercising, particularly walking • Skin care • Regular dental examinations • Artificial tears for dry eyes 13

  13. Primary Biliary Cholangitis: References and Further Resources • • American Liver Foundation Hartford Hospital Comprehensive Connecticut Division Liver Center 127 Washington Avenue 85 Seymour Street North Haven, CT 06473 Suite 320 (203) 234-2022 Hartford, CT 06106 liverfoundation.org/chapters/CTALF (860) 972-4219 http://www.liverfoundation.org/abouttheliv www.hartfordhospital.org/contact- er/info/pbc us/comprehensive-liver-center • • National Organization for Rare The National Institute of Diabetes and Disorders (NORD) Digestive and Kidney Diseases National Headquarters www.niddk.nih.gov/health- 55 Kenosia Avenue information/health-topics/liver- Danbury, CT 06810 disease/primary-biliary-cirrhosis (203) 744-0100 • Interconnect Support Services www.rarediseases.org (844) 622-4278 • Yale Liver Center www.interconnectsupport.com 300 Cedar Street, Room S241 New Haven, CT 06520 (203) 785-5279 www.livercenter.yale.edu 14

  14. Primary Biliary Cholangitis: References and Further Resources (cont.) • • PBCers PBC Society (Largest PBC online support group, with (Canadian organization with regional almost 3000 members worldwide) groups that provide support and PBCers Organization encouragement, education and 1430 Garden Road information, and fundraising for research Pearland, TX 77581 on PBC) PBCersOrg96@aol.com Canadian PBC Society www.PBCers.org 4936 Yonge Street, Suite 221 Toronto, Ontario M2N6S3 • PBC Foundation info@pbc-society.ca (UK-based patient organization with www.PBC-Society.ca nearly 10,000 members that provides • support to people around the world who National Institutes of Health are living with PBC, as well as their www.nih.gov families and friends) • Mayo Clinic The PBC Foundation www.mayoclinic.org 2 York Place Edinburgh EH1 3EP info@pbcfoundation.org.uk www.PBCFoundation.org.uk 15

Recommend Documents


authorisation of ocaliva for pbc in the eu
Authorisation of Ocaliva for PBC in the

Authorisation of Ocaliva for PBC in the EU EMA stakeholder interaction on the

what s new in hepatology aasld 2016
Whats new in Hepatology AASLD 2016

Whats new in Hepatology AASLD 2016 CWN Spearman C Kassianides Whats new in

immunology of primary sclerosing cholangitis
Immunology of Primary Sclerosing

Immunology of Primary Sclerosing Cholangitis John M. Vierling, M.D., F.A.C.P.

manish dutta institute of liver and biliary sciences
Manish Dutta, Institute of Liver and

Manish Dutta, Institute of Liver and Biliary Sciences INSTITUTE OF LIVER &

malignant obstructive jaundice
malignant obstructive jaundice By

1. Biliary Drainage vs. No Biliary Drainage 2. Patency of Biliary Stents in

biliary ultrasonography
Biliary Ultrasonography Kathleen

3/22/2016 Biliary Ultrasonography Kathleen OBrien

biliary system anatomy and physiology review
Biliary System: Anatomy and Physiology

Biliary System: Anatomy and Physiology Review Katherine Mansfield RN,CGN,MN

gallbladder bile ducts anatomy biliary disease and
Gallbladder & Bile Ducts Anatomy

29/01/2013 Gallbladder & Bile Ducts Anatomy Biliary Disease and

at the chris hani baragwanath
AT THE CHRIS HANI BARAGWANATH ACADEMIC

LATE PRESENTATION BILIARY ATRESIA AT THE CHRIS HANI BARAGWANATH ACADEMIC

michael trauner div of gastroenterology amp hepatology
Michael Trauner Div. of

Session 2: Primary Sclerosing Cholangitis (PSC) Potential trial design and

over super broadband i nt ernet
over super-broadband I nt ernet

Asia- - Pacif ic Medical Network Project Pacif ic Medical Network Project

the coagulation conundrum
The Coagulation Conundrum:

The Coagulation Conundrum: Perioperative Management and

international conference on occupational radiation
International Conference on

International Conference on Occupational Radiation Protection Vienna, 4 th

child welfare
Child Welfare: Legal Leaders at the

Trauma-Informed Systems Change in Child Welfare: Legal Leaders at the

welcome
WELCOME First & foremost safety

WELCOME First & foremost safety WELCOME Every PowerPoint presentation

safe infant sleeping addressing sudden unexpected infant
Safe Infant Sleeping: Addressing Sudden

Safe Infant Sleeping: Addressing Sudden Unexpected Infant Death in

agitg 2017 implementation v innovation what rules in my
AGITG 2017 Implementation v Innovation

AGITG 2017 Implementation v Innovation What rules in my world? Managing

phase ib study results subgroup efficacy analysis of
Phase Ib Study Results: Subgroup

Phase Ib Study Results: Subgroup Efficacy Analysis of Atezolizumab +

1 important notice these slides the quot document quot
1 Important notice These slides (the

18 th February 2016 Julian Smith, Chief Financial Officer 1 Important notice

what is vitamin d 3
What is Vitamin D 3 ? Vitamin D3 has a

D 3 Vitamin 400 IU What is Vitamin D 3 ? Vitamin D3 has a significant role

associated factors among older
associated factors among older adults

Vitamin D deficiency and its associated factors among older adults in Alborz